ResMed Provides Update on Phase III SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy In Central Sleep Apnea and Chronic Heart Failure
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Jefferies Drops Price Target After ResMed (RMD) Heart Failure Trial Fails
May 14, 2015 10:19 AM EDTJefferies maintains a Hold rating on ResMed (NYSE: RMD), and lowered the price target to $52.00 (from $65.00), following SERVE Heart Failure trial. Analyst Raj Denhoy said that the trial showed an increase in cardiovascular mortality in low EF heart failure patients. "The finding all but ends... More
BofA/Merrill Lynch Downgrades ResMed (RMD) to Neutral
May 13, 2015 8:44 AM EDTBofA/Merrill Lynch downgraded ResMed (NYSE: RMD) from Buy to Neutral. Earlier ResMed announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint.
For an analyst ratings summary and ratings history on ResMed... More
ResMed (RMD) Announces SERVE-HF Missed Primary Endpoint
May 13, 2015 6:14 AM EDTResMed (NYSE: RMD) announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint. SERVE-HF was designed to assess whether the treatment of moderate to severe predominant central sleep apnea with Adaptive Servo-Ventilation (ASV) therapy could reduce mortality and morbidity in patients with symptomatic chronic heart failure in addition to optimized medical care.
The study did not show a statistically significant difference between patients randomized to ASV therapy and those in the control group in the primary endpoint of time to all-cause mortality or unplanned hospitalization... More
